Breaking News Instant updates and real-time market news.

RAVN

Raven

$24.29 /

+0.63 (+2.66%)

16:03
11/24/20
11/24
16:03
11/24/20
16:03

Raven CEO says company 'well-positioned for substantial long-term growth'

"We are well-positioned for substantial long-term growth across all three of our operating divisions," said CEO Dan Rykhus. "This confidence stems from the opportunities in front of us combined with our performance throughout the first three quarters of fiscal 2021. In Applied Technology, we generated strong margins in our underlying business, and economic conditions in the ag market appear to be improving for the first time in several years. In Engineered Films, our operational discipline and ability to generate significant cash flows in the midst of this pandemic is evidence of our strong business model. Additionally, Aerostar continues to prove the value of Thunderhead, creating momentum for strong growth in both the short-term and the long-term," concluded Rykhus.

RAVN Raven
$24.29 /

+0.63 (+2.66%)

06/19/20
Fly Intel: Top five analyst initiations
06/19/20 Oppenheimer
Raven initiated with an Outperform at Oppenheimer
06/18/20 Oppenheimer
Raven initiated with an Outperform at Oppenheimer
03/25/20 National Securities
Raven upgraded to Buy from Neutral at National Securities

TODAY'S FREE FLY STORIES

General news
FX Action: USD-CAD has recouped » 04:05
01/27/21
01/27
04:05
01/27/21
04:05

FX Action: USD-CAD has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
FX Update: The dollar and most currencies have remained in idling mode » 03:35
01/27/21
01/27
03:35
01/27/21
03:35

FX Update: The dollar and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

General news
FOMC Preview: » 01:55
01/27/21
01/27
01:55
01/27/21
01:55

FOMC Preview: No changes…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
Asian market Update: » 01:40
01/27/21
01/27
01:40
01/27/21
01:40

Asian market Update:…

Asian market Update: There wasn't a lot of movement in markets overnight, with traders clearly cautious ahead of the FOMC announcement today. Major indices are narrowly mixed. The ASX underperformed in catch up trade, while Nikkei and Hang Seng managed modest gains. NASDAQ futures are up 0.5% after positive earnings from Microsoft, but other U.S. futures are in the red. The Nikkei is currently up 0.3%, the Hang Seng 0.08%, while the CSI 300 is down -0.01% and the ASX -0.65%. Treasury yields are little changed, while in FX markets USD-JPY has lifted to 103.68. The front end WTI future meanwhile is trading at USD 52.98 per barrel.

General news
U.S. durable goods preview » 01:40
01/27/21
01/27
01:40
01/27/21
01:40

U.S. durable goods…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Earnings
Notable companies reporting before tomorrow's open » 20:25
01/26/21
01/26
20:25
01/26/21
20:25
T

AT&T

$29.71 /

+0.6 (+2.06%)

, ABT

Abbott

$114.73 /

+0.01 (+0.01%)

, BA

Boeing

$201.95 /

-1.48 (-0.73%)

, ANTM

Anthem

$312.51 /

-2.83 (-0.90%)

, BX

Blackstone

$65.07 /

+0.035 (+0.05%)

, ADP

ADP

$164.48 /

+0.93 (+0.57%)

, PGR

Progressive

$91.63 /

-0.91 (-0.98%)

, GD

General Dynamics

$150.29 /

-2.95 (-1.93%)

, APH

Amphenol

$130.06 /

-2.7 (-2.03%)

, VFC

VF Corp.

$85.18 /

+0.35 (+0.41%)

, GLW

Corning

$37.18 /

-1.28 (-3.33%)

, TXT

Textron

$49.70 /

-0.295 (-0.59%)

, KNX

Knight-Swift

$44.53 /

-0.51 (-1.13%)

, NYCB

New York Community Bancorp

$10.96 /

-0.07 (-0.63%)

, EAT

Brinker

$62.51 /

-1.63 (-2.54%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include AT&T (T), consensus 73c... Abbott (ABT), consensus $1.35... Boeing (BA), consensus ($1.80)... Anthem (ANTM), consensus $2.52... Blackstone (BX), consensus 88c... ADP (ADP), consensus $1.29... Progressive (PGR), consensus $1.66... General Dynamics (GD), consensus $3.54... Amphenol (APH), consensus $1.02... V.F. Corp. (VFC), consensus 90c... Corning (GLW), consensus 48c... Textron (TXT), consensus 91c... Knight-Swift (KNX), consensus 91c... New York Community Bancorp (NYCB), consensus 26c... Brinker International (EAT), consensus 33c.

ShowHide Related Items >><<
VFC VF Corp.
$85.18 /

+0.35 (+0.41%)

TXT Textron
$49.70 /

-0.295 (-0.59%)

T AT&T
$29.71 /

+0.6 (+2.06%)

NYCB New York Community Bancorp
$10.96 /

-0.07 (-0.63%)

KNX Knight-Swift
$44.53 /

-0.51 (-1.13%)

GLW Corning
$37.18 /

-1.28 (-3.33%)

GD General Dynamics
$150.29 /

-2.95 (-1.93%)

EAT Brinker
$62.51 /

-1.63 (-2.54%)

BX Blackstone
$65.07 /

+0.035 (+0.05%)

BA Boeing
$201.95 /

-1.48 (-0.73%)

APH Amphenol
$130.06 /

-2.7 (-2.03%)

ANTM Anthem
$312.51 /

-2.83 (-0.90%)

ADP ADP
$164.48 /

+0.93 (+0.57%)

ABT Abbott
$114.73 /

+0.01 (+0.01%)

T AT&T
$29.71 /

+0.6 (+2.06%)

01/04/21
Fly Intel: Top five analyst upgrades
01/04/21 Raymond James
AT&T upgraded to Outperform from Market Perform at Raymond James
01/04/21 Raymond James
AT&T upgraded to Outperform from Market Perform at Raymond James
12/24/20 Raymond James
AT&T estimates lowered ahead of Q4 report at Raymond James
ABT Abbott
$114.73 /

+0.01 (+0.01%)

01/22/21 JPMorgan
JPMorgan confident Abbott results will beat Q4 estimates
12/10/20 Stifel
DexCom has 'significantly more' growth still to come, says Stifel
11/20/20 Piper Sandler
DexCom secured national reimbursement in France, says Piper Sandler
11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
BA Boeing
$201.95 /

-1.48 (-0.73%)

01/20/21
Fly Intel: Top five analyst upgrades
01/20/21 Berenberg
Boeing upgraded to Hold from Sell at Berenberg
01/04/21
Fly Intel: Top five analyst downgrades
01/04/21 Baird
Boeing elevated to Fresh Pick at Baird
ANTM Anthem
$312.51 /

-2.83 (-0.90%)

01/26/21 Cowen
Anthem price target raised to $360 from $330 at Cowen
01/15/21 Jefferies
Anthem upgraded to Buy on more constructive commercial outlook at Jefferies
01/15/21 Jefferies
Anthem upgraded to Buy from Hold at Jefferies
01/13/21 Argus
Anthem price target raised to $380 from $300 at Argus
BX Blackstone
$65.07 /

+0.035 (+0.05%)

01/14/21
Fly Intel: Top five analyst initiations
01/14/21 Piper Sandler
Blackstone initiated with an Overweight at Piper Sandler
10/29/20 Oppenheimer
Blackstone upgraded to Outperform at Oppenheimer
10/29/20 Oppenheimer
Blackstone upgraded to Outperform from Perform at Oppenheimer
ADP ADP
$164.48 /

+0.93 (+0.57%)

01/12/21 Evercore ISI
ADP downgraded to Underperform from Outperform at Evercore ISI
12/18/20 Wells Fargo
ADP resumed with an Overweight at Wells Fargo
11/09/20 Credit Suisse
ADP price target raised to $190 from $185 at Credit Suisse
11/02/20 Barclays
ADP price target raised to $180 from $145 at Barclays
PGR Progressive
$91.63 /

-0.91 (-0.98%)

01/13/21 Gordon Haskett
Allstate lowering auto rates by 5% in several states, says Gordon Haskett
01/08/21 Goldman Sachs
Progressive downgraded to Sell from Neutral at Goldman Sachs
01/07/21 B. Riley Securities
Progressive price target raised to $96 from $88 at B. Riley Securities
01/04/21 Wells Fargo
Progressive downgraded to Underweight from Equal Weight at Wells Fargo
GD General Dynamics
$150.29 /

-2.95 (-1.93%)

11/03/20 Morgan Stanley
Morgan Stanley sees attractive buying opportunity in Defense stocks
10/29/20 Credit Suisse
General Dynamics price target lowered to $140 from $156 at Credit Suisse
10/02/20
Fly Intel: Top five analyst downgrades
10/02/20 Baird
Baird downgrades General Dynamics, sees no 'material' Gulfstream ramp
APH Amphenol
$130.06 /

-2.7 (-2.03%)

01/19/21 Baird
Baird incrementally positive on ITW's MTS test & simulation business acquisition
12/29/20 JPMorgan
Amphenol reinstated with a Neutral at JPMorgan
10/19/20 Baird
Amphenol initiated with an Outperform at Baird
09/15/20 UBS
Amphenol initiated with a Buy at UBS
VFC VF Corp.
$85.18 /

+0.35 (+0.41%)

01/25/21 Cowen
VF Corp. price target raised to $99 from $91 at Cowen
01/25/21 Pivotal Research
VF Corp. price target raised to $86 from $76 at Pivotal Research
01/22/21 Williams Capital
VF Corp. initiated with a Buy at Williams Trading
01/21/21 Deutsche Bank
VF Corp. upgraded to Buy from Hold at Deutsche Bank
GLW Corning
$37.18 /

-1.28 (-3.33%)

01/14/21 Barclays
Corning upgraded to Overweight with $44 target at Barclays
01/14/21 Barclays
Corning upgraded to Overweight from Equal Weight at Barclays
01/06/21
Fly Intel: Top five analyst initiations
01/06/21 UBS
Corning initiated with a Buy at UBS
TXT Textron
$49.70 /

-0.295 (-0.59%)

01/07/21 Baird
Textron downgraded to Neutral from Outperform at Baird
11/17/20 Susquehanna
Textron upgraded to Positive from Neutral at Susquehanna
11/17/20 Susquehanna
Textron upgraded to Positive from Neutral at Susquehanna
10/01/20 Cowen
Textron downgraded to Market Perform from Outperform at Cowen
KNX Knight-Swift
$44.53 /

-0.51 (-1.13%)

01/14/21 Citi
Knight-Swift price target raised to $48 from $46 at Citi
01/07/21 Wolfe Research
Knight-Swift downgraded to Peer Perform from Outperform at Wolfe Research
12/04/20
Evercore starts trucking coverage with preference for Old Dominion, Saia
12/04/20 Evercore ISI
Knight-Swift initiated with an In Line at Evercore ISI
NYCB New York Community Bancorp
$10.96 /

-0.07 (-0.63%)

01/15/21 Compass Point
New York Community Bancorp upgraded to Buy from Neutral at Compass Point
11/06/20 Morgan Stanley
New York Community Bancorp upgraded to Equal Weight at Morgan Stanley
11/06/20 Morgan Stanley
New York Community upgraded to Equal Weight from Underweight at Morgan Stanley
04/14/20 Compass Point
New York Community Bancorp initiated with a Neutral at Compass Point
EAT Brinker
$62.51 /

-1.63 (-2.54%)

01/25/21 Loop Capital
Brinker price target raised to $75 from $61 at Loop Capital
01/21/21 Piper Sandler
Brinker price target raised to $70 from $61 at Piper Sandler
01/19/21 Goldman Sachs
Brinker initiated with a Buy at Goldman Sachs
01/04/21 Stephens
Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens
VFC VF Corp.
$85.18 /

+0.35 (+0.41%)

TXT Textron
$49.70 /

-0.295 (-0.59%)

T AT&T
$29.71 /

+0.6 (+2.06%)

PGR Progressive
$91.63 /

-0.91 (-0.98%)

NYCB New York Community Bancorp
$10.96 /

-0.07 (-0.63%)

KNX Knight-Swift
$44.53 /

-0.51 (-1.13%)

GLW Corning
$37.18 /

-1.28 (-3.33%)

GD General Dynamics
$150.29 /

-2.95 (-1.93%)

EAT Brinker
$62.51 /

-1.63 (-2.54%)

BX Blackstone
$65.07 /

+0.035 (+0.05%)

BA Boeing
$201.95 /

-1.48 (-0.73%)

APH Amphenol
$130.06 /

-2.7 (-2.03%)

ANTM Anthem
$312.51 /

-2.83 (-0.90%)

ADP ADP
$164.48 /

+0.93 (+0.57%)

ABT Abbott
$114.73 /

+0.01 (+0.01%)

  • 07
    May
VFC VF Corp.
$85.18 /

+0.35 (+0.41%)

T AT&T
$29.71 /

+0.6 (+2.06%)

GD General Dynamics
$150.29 /

-2.95 (-1.93%)

BX Blackstone
$65.07 /

+0.035 (+0.05%)

BA Boeing
$201.95 /

-1.48 (-0.73%)

ANTM Anthem
$312.51 /

-2.83 (-0.90%)

ABT Abbott
$114.73 /

+0.01 (+0.01%)

VFC VF Corp.
$85.18 /

+0.35 (+0.41%)

TXT Textron
$49.70 /

-0.295 (-0.59%)

T AT&T
$29.71 /

+0.6 (+2.06%)

PGR Progressive
$91.63 /

-0.91 (-0.98%)

GLW Corning
$37.18 /

-1.28 (-3.33%)

GD General Dynamics
$150.29 /

-2.95 (-1.93%)

EAT Brinker
$62.51 /

-1.63 (-2.54%)

BX Blackstone
$65.07 /

+0.035 (+0.05%)

BA Boeing
$201.95 /

-1.48 (-0.73%)

ANTM Anthem
$312.51 /

-2.83 (-0.90%)

ADP ADP
$164.48 /

+0.93 (+0.57%)

ABT Abbott
$114.73 /

+0.01 (+0.01%)

TXT Textron
$49.70 /

-0.295 (-0.59%)

T AT&T
$29.71 /

+0.6 (+2.06%)

KNX Knight-Swift
$44.53 /

-0.51 (-1.13%)

GLW Corning
$37.18 /

-1.28 (-3.33%)

EAT Brinker
$62.51 /

-1.63 (-2.54%)

BX Blackstone
$65.07 /

+0.035 (+0.05%)

BA Boeing
$201.95 /

-1.48 (-0.73%)

ANTM Anthem
$312.51 /

-2.83 (-0.90%)

ADP ADP
$164.48 /

+0.93 (+0.57%)

ABT Abbott
$114.73 /

+0.01 (+0.01%)

Recommendations
Agios' Mitapivat on track as first approved therapy in PKD patients, says Piper » 20:13
01/26/21
01/26
20:13
01/26/21
20:13
AGIO

Agios Pharmaceuticals

$48.08 /

-1.45 (-2.93%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren keeps his Overweight rating and $80 price target on Agios Pharmaceuticals after the company announced that its ACTIVATE-T trial of mitapivat in regularly transfused adults with PK deficiency demonstrated a statistically significant and clinically meaningful reduction in transfusion burden. Mitapivat is on track to become the first approved therapy for PKD patients, with Agios anticipating a filing for regulatory approval in the U.S. in Q2 of this year, which could lead to two potential 2022 launches, the analyst tells investors in a research note.

ShowHide Related Items >><<
AGIO Agios Pharmaceuticals
$48.08 /

-1.45 (-2.93%)

AGIO Agios Pharmaceuticals
$48.08 /

-1.45 (-2.93%)

01/14/21 Barclays
Agios Pharmaceuticals price target raised to $58 from $50 at Barclays
12/23/20 Citi
Agios shares 'significantly undervalued at this point,' says Citi
12/22/20 SVB Leerink
Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink
12/22/20 Cantor Fitzgerald
Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald
AGIO Agios Pharmaceuticals
$48.08 /

-1.45 (-2.93%)

Downgrade
Visa downgraded to Sector Weight from Overweight at KeyBanc » 20:06
01/26/21
01/26
20:06
01/26/21
20:06
V

Visa

$202.01 /

+1.03 (+0.51%)

KeyBanc analyst Josh Beck…

KeyBanc analyst Josh Beck downgraded Visa to Sector Weight from Overweight with a $210 price target.

ShowHide Related Items >><<
V Visa
$202.01 /

+1.03 (+0.51%)

V Visa
$202.01 /

+1.03 (+0.51%)

01/26/21 Bernstein
Visa reinstated with an Outperform at Bernstein
01/14/21 Deutsche Bank
Visa price target raised to $270 from $220 at Deutsche Bank
01/13/21
Fly Intel: Top five analyst upgrades
01/13/21 KeyBanc
Visa price target raised to $225 from $210 at KeyBanc
V Visa
$202.01 /

+1.03 (+0.51%)

  • 13
    Oct
V Visa
$202.01 /

+1.03 (+0.51%)

V Visa
$202.01 /

+1.03 (+0.51%)

V Visa
$202.01 /

+1.03 (+0.51%)

Downgrade
MasterCard downgraded to Sector Weight from Overweight at KeyBanc » 20:05
01/26/21
01/26
20:05
01/26/21
20:05
MA

MasterCard

$327.71 /

-1.565 (-0.48%)

KeyBanc analyst Josh Beck…

KeyBanc analyst Josh Beck downgraded MasterCard to Sector Weight from Overweight with a $345 price target.

ShowHide Related Items >><<
MA MasterCard
$327.71 /

-1.565 (-0.48%)

MA MasterCard
$327.71 /

-1.565 (-0.48%)

01/25/21 Barclays
MasterCard price target raised to $380 from $360 at Barclays
01/14/21 Deutsche Bank
MasterCard price target raised to $420 from $383 at Deutsche Bank
01/13/21
Fly Intel: Top five analyst upgrades
01/13/21 Jefferies
Jefferies upgrades 'high-quality recovery play' MasterCard to Buy
MA MasterCard
$327.71 /

-1.565 (-0.48%)

MA MasterCard
$327.71 /

-1.565 (-0.48%)

MA MasterCard
$327.71 /

-1.565 (-0.48%)

MA MasterCard
$327.71 /

-1.565 (-0.48%)

Hot Stocks
Guardant Health CEO sells 160.9K shares of common stock » 19:40
01/26/21
01/26
19:40
01/26/21
19:40
GH

Guardant Health

$149.95 /

-7.27 (-4.62%)

In a regulatory filing,…

In a regulatory filing, Guardant Health disclosed that its CEO Helmy Eltoukhy sold 160.9K shares of common stock on January 22nd in a total transaction size of $25.6M, reducing his stake by about 5%.

ShowHide Related Items >><<
GH Guardant Health
$149.95 /

-7.27 (-4.62%)

GH Guardant Health
$149.95 /

-7.27 (-4.62%)

01/21/21 Citi
Citi adds Tandem, removes Guardant from 'Value Creators' list
01/14/21 Canaccord
Natera price target raised to $125 from $112 at Canaccord
01/12/21 Canaccord
Guardant Health price target raised to $170 from $145 at Canaccord
01/11/21
Fly Intel: Top five analyst initiations
GH Guardant Health
$149.95 /

-7.27 (-4.62%)

  • 07
    Oct
  • 02
    Jun
GH Guardant Health
$149.95 /

-7.27 (-4.62%)

Hot Stocks
BioXcel Therapeutics granted FDA Orphan Drug Designation for Talabostat » 19:30
01/26/21
01/26
19:30
01/26/21
19:30
BTAI

BioXcel Therapeutics

$51.39 /

+1.52 (+3.05%)

BioXcel Therapeutics…

BioXcel Therapeutics announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for Talabostat for the treatment of soft tissue sarcoma. Reference Link

ShowHide Related Items >><<
BTAI BioXcel Therapeutics
$51.39 /

+1.52 (+3.05%)

BTAI BioXcel Therapeutics
$51.39 /

+1.52 (+3.05%)

01/06/21 H.C. Wainwright
BioXcel Therapeutics price target raised to $185 from $175 at H.C. Wainwright
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Goldman Sachs
BioXcel Therapeutics initiated with a Buy at Goldman Sachs
09/02/20 Jefferies
BioXcel Therapeutics initiated with a Buy at Jefferies
BTAI BioXcel Therapeutics
$51.39 /

+1.52 (+3.05%)

  • 29
    Jul
  • 20
    Feb
BTAI BioXcel Therapeutics
$51.39 /

+1.52 (+3.05%)

Initiation
Berkeley Lights initiated with a Buy at Stifel » 19:27
01/26/21
01/26
19:27
01/26/21
19:27
BLI

Berkeley Lights

$73.07 /

-6.93 (-8.66%)

Stifel analyst Daniel…

Stifel analyst Daniel Arias initiated coverage of Berkeley Lights with a Buy rating and $105 price target.

ShowHide Related Items >><<
BLI Berkeley Lights
$73.07 /

-6.93 (-8.66%)

BLI Berkeley Lights
$73.07 /

-6.93 (-8.66%)

11/13/20 JPMorgan
Berkeley Lights price target raised to $100 from $75 at JPMorgan
11/09/20 KeyBanc
Berkeley Lights initiated with an Overweight at KeyBanc
08/11/20
Fly Intel: Top five analyst initiations
08/11/20 JPMorgan
JPMorgan starts 'industry pioneer' Berkeley Lights at Overweight
BLI Berkeley Lights
$73.07 /

-6.93 (-8.66%)

  • 19
    Nov
  • 17
    Jul
BLI Berkeley Lights
$73.07 /

-6.93 (-8.66%)

Hot Stocks
Sorrento Therapeutics jumps 5% to $11 after positive COVI-MSC study data  19:20
01/26/21
01/26
19:20
01/26/21
19:20
SRNE

Sorrento Therapeutics

$10.40 /

+1.11 (+11.95%)

 
ShowHide Related Items >><<
SRNE Sorrento Therapeutics
$10.40 /

+1.11 (+11.95%)

SRNE Sorrento Therapeutics
$10.40 /

+1.11 (+11.95%)

01/21/21 Alliance Global Partners
Sorrento Therapeutics initiated with a Buy at Alliance Global Partners
07/31/20 H.C. Wainwright
Sorrento Therapeutics price target raised to $30 from $24 at H.C. Wainwright
07/20/20 Dawson James
Sorrento antibody cocktail effort could move quickly, says Dawson James
05/26/20 Dawson James
Sorrento Therapeutics initiated with a Buy at Dawson James
SRNE Sorrento Therapeutics
$10.40 /

+1.11 (+11.95%)

SRNE Sorrento Therapeutics
$10.40 /

+1.11 (+11.95%)

Hot Stocks
Rush Street Interactive to launch BetRivers.com online sportsbook in Virginia » 19:19
01/26/21
01/26
19:19
01/26/21
19:19
RSI

Rush Street Interactive

$21.01 /

-0.85 (-3.89%)

Rush Street Interactive…

Rush Street Interactive announced the launch of its flagship brand and industry leading online sportsbook, BetRivers.com, in Virginia. Beginning tomorrow, sports enthusiasts across the Commonwealth of Virginia will be able to register, deposit funds and place bets at BetRivers.com on their favorite teams and events safely from their mobile devices and computers.

ShowHide Related Items >><<
RSI Rush Street Interactive
$21.01 /

-0.85 (-3.89%)

RSI Rush Street Interactive
$21.01 /

-0.85 (-3.89%)

01/26/21
Fly Intel: Top five analyst initiations
01/26/21 Goldman Sachs
Rush Street Interactive initiated with a Neutral at Goldman Sachs
01/22/21
Fly Intel: Top five analyst initiations
01/22/21 Needham
Rush Street Interactive initiated with a Buy at Needham
RSI Rush Street Interactive
$21.01 /

-0.85 (-3.89%)

RSI Rush Street Interactive
$21.01 /

-0.85 (-3.89%)

RSI Rush Street Interactive
$21.01 /

-0.85 (-3.89%)

Hot Stocks
Sorrento reports 'positive' preliminary results of Phase 1b COVID-MSC study » 19:11
01/26/21
01/26
19:11
01/26/21
19:11
SRNE

Sorrento Therapeutics

$10.40 /

+1.11 (+11.95%)

Sorrento Therapeutics…

Sorrento Therapeutics announced positive preliminary results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells for patients suffering from COVID-19-induced acute respiratory distress or acute respiratory distress syndrome. This ongoing study iss a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy of COVI-MSCs administered every other day for three infusions for a total of 1 x 106 cells/kg. The primary objective is to evaluate the safety of intravenous infusion of allogeneic adipose MSC cells in patients with COVID-19-induced ARD or ARDS. The secondary objective is to evaluate efficacy outcome variables to give guidance regarding the risk/benefit ratio in patients with COVID-19 respiratory distress. The first three patients enrolled tolerated treatment well and improved rapidly. Each of the three patients was discharged from the hospital within a week of starting the patient's COVI-MSC infusions and two patients were discharged on the day of their last infusion. One of the patients had been in the hospital for three weeks, unable to be weaned from significant oxygen support, and another patient with uncontrolled diabetes had been discharged previously but had to be readmitted due to recurrent ARD. Each of the infusions were well-tolerated and no patient reported any infusion-related adverse events. A fourth patient is currently at the beginning of a course of treatment, with no safety issues following the patient's first infusion. Additional enrollment continues.

ShowHide Related Items >><<
SRNE Sorrento Therapeutics
$10.40 /

+1.11 (+11.95%)

SRNE Sorrento Therapeutics
$10.40 /

+1.11 (+11.95%)

01/21/21 Alliance Global Partners
Sorrento Therapeutics initiated with a Buy at Alliance Global Partners
07/31/20 H.C. Wainwright
Sorrento Therapeutics price target raised to $30 from $24 at H.C. Wainwright
07/20/20 Dawson James
Sorrento antibody cocktail effort could move quickly, says Dawson James
05/26/20 Dawson James
Sorrento Therapeutics initiated with a Buy at Dawson James
SRNE Sorrento Therapeutics
$10.40 /

+1.11 (+11.95%)

SRNE Sorrento Therapeutics
$10.40 /

+1.11 (+11.95%)

Hot Stocks
Target, Levi Strauss expand partnership with limited-edition collection » 19:06
01/26/21
01/26
19:06
01/26/21
19:06
TGT

Target

$187.74 /

-2.33 (-1.23%)

, LEVI

Levi Strauss

$21.35 /

+0.13 (+0.61%)

Target Corporation (TGT)…

Target Corporation (TGT) announced a limited-edition collection with Levi Strauss & Co. (LEVI), featuring an assortment of home and lifestyle items and marking Levi's first Home partnership. Reinventing what a retailer's relationship with a national brand can represent, the Levi's for Target limited-edition Home collection builds on the decade-long partnership between the two iconic companies, which began with the introduction of the DENIZEN from Levi's value denim brand, and expanded in 2019 with the introduction of Levi's Red Tab brand at Target. As part of the Red Tab expansion, Target is rolling out curated in-store displays to be set in 500 stores by Fall 2021. The new Levi's for Target limited-edition collection launches Feb. 28, 2021. Available at Target.com and in most Target stores, the collection features thoughtfully-designed, durable pieces meant to inspire a more sustainable home and life.

ShowHide Related Items >><<
TGT Target
$187.74 /

-2.33 (-1.23%)

LEVI Levi Strauss
$21.35 /

+0.13 (+0.61%)

TGT Target
$187.74 /

-2.33 (-1.23%)

01/14/21 DA Davidson
Target price target raised to $229 from $208 at DA Davidson
01/14/21 Cowen
Target price target raised to $230 from $190 at Cowen
01/14/21 Deutsche Bank
Target price target raised to $211 from $194 at Deutsche Bank
01/13/21 KeyBanc
Target price target raised to $235 from $180 at KeyBanc
LEVI Levi Strauss
$21.35 /

+0.13 (+0.61%)

01/07/21 JPMorgan
Levi Strauss price target raised to $21 from $18 at JPMorgan
12/30/20 Guggenheim
Levi Strauss price target raised to $24 from $20 at Guggenheim
12/10/20
Fly Intel: Top five analyst upgrades
12/10/20 Goldman Sachs
Levi Strauss upgraded to Buy from Sell at Goldman Sachs
TGT Target
$187.74 /

-2.33 (-1.23%)

LEVI Levi Strauss
$21.35 /

+0.13 (+0.61%)

TGT Target
$187.74 /

-2.33 (-1.23%)

TGT Target
$187.74 /

-2.33 (-1.23%)

LEVI Levi Strauss
$21.35 /

+0.13 (+0.61%)

TGT Target
$187.74 /

-2.33 (-1.23%)

LEVI Levi Strauss
$21.35 /

+0.13 (+0.61%)

Hot Stocks
Walgreens Boots Alliances confirms appointment of Rosalind Brewer as CEO » 19:02
01/26/21
01/26
19:02
01/26/21
19:02
WBA

Walgreens Boots Alliance

$49.18 /

+1.36 (+2.84%)

, SBUX

Starbucks

$104.69 /

+1.34 (+1.30%)

Walgreens Boots Alliance…

Walgreens Boots Alliance (WBA) announced the appointment of RosalindBrewer as the company's Chief Executive Officer, effective on March 15, 2021. Brewer will also join the WBA Board of Directors upon assuming the role. She succeeds Stefano Pessina who, as previously announced, will transition to the role of Executive Chairman of the Board of WBA. Pessina has served as the CEO of the combined company for six years following the merger between Walgreens and Alliance Boots in December 2014. During his tenure, he transformed and modernized the company into a global pharmacy, health and wellness leader, significantly expanding WBA's retail footprint and investing in digitalization. Pessina will replace James Skinner as Executive Chairman of WBA in March 2021. Skinner will remain on the WBA Board as a non-executive director to facilitate a smooth leadership transition. Brewer most recently served as Chief Operating Officer, Group President and member of the Board of Directors of Starbucks Corporation (SBUX), where she has been instrumental in helping the company accelerate its growth strategy, expand its global reach and drive value for all of Starbucks' diverse stakeholders.

ShowHide Related Items >><<
WBA Walgreens Boots Alliance
$49.18 /

+1.36 (+2.84%)

SBUX Starbucks
$104.69 /

+1.34 (+1.30%)

WBA Walgreens Boots Alliance
$49.18 /

+1.36 (+2.84%)

01/15/21 Baird
Walgreens Boots Alliance price target raised to $64 from $55 at Baird
01/11/21
Fly Intel: Top five analyst upgrades
01/11/21 Baird
Baird upgrades Walgreens Boots Alliance following Q1 results
01/11/21 Guggenheim
Walgreens Boots Alliance upgraded to Buy from Neutral at Guggenheim
SBUX Starbucks
$104.69 /

+1.34 (+1.30%)

01/21/21 MKM Partners
Starbucks' Q1 may show slowdown in U.S. comp trends, says MKM Partners
01/19/21 Goldman Sachs
Starbucks initiated with a Buy at Goldman Sachs
01/14/21 Cleveland Research
Cleveland Research lowers Starbucks Q1 Americas comps forecast
12/16/20 Stephens
Starbucks pointed to softer U.S., stronger China than expected, says Stephens
WBA Walgreens Boots Alliance
$49.18 /

+1.36 (+2.84%)

SBUX Starbucks
$104.69 /

+1.34 (+1.30%)

WBA Walgreens Boots Alliance
$49.18 /

+1.36 (+2.84%)

SBUX Starbucks
$104.69 /

+1.34 (+1.30%)

WBA Walgreens Boots Alliance
$49.18 /

+1.36 (+2.84%)

SBUX Starbucks
$104.69 /

+1.34 (+1.30%)

WBA Walgreens Boots Alliance
$49.18 /

+1.36 (+2.84%)

SBUX Starbucks
$104.69 /

+1.34 (+1.30%)

On The Fly
Fly Intel: After-Hours Movers » 18:43
01/26/21
01/26
18:43
01/26/21
18:43
TRMK

Trustmark

$30.19 /

-0.47 (-1.53%)

, COF

Capital One

$99.96 /

-2.62 (-2.55%)

, MSFT

Microsoft

$232.59 /

+3.11 (+1.36%)

, CHRW

C.H. Robinson

$97.35 /

-2.04 (-2.05%)

, WBA

Walgreens Boots Alliance

$49.18 /

+1.36 (+2.84%)

, CTMX

CytomX Therapeutics

$6.92 /

-0.19 (-2.67%)

, LRN

Stride

$26.08 /

+0.77 (+3.04%)

, FFIV

F5 Networks

$208.58 /

+1.33 (+0.64%)

, HOPE

Hope Bancorp

$12.13 /

-0.16 (-1.30%)

, MXIM

Maxim Integrated

$93.13 /

+0.77 (+0.83%)

, AGYS

Agilysys

$49.90 /

+1.44 (+2.97%)

, TXN

Texas Instruments

$171.48 /

-1.43 (-0.83%)

, SBUX

Starbucks

$104.69 /

+1.34 (+1.30%)

, NAVI

Navient

$11.88 /

+0.57 (+5.04%)

, TTOO

T2 Biosystems

$2.81 /

+0.715 (+34.13%)

, PLUG

Plug Power

$73.14 /

+7.38 (+11.22%)

, PSNL

Personalis

$42.48 /

-4.49 (-9.56%)

Check out this evening's…

ShowHide Related Items >><<
WBA Walgreens Boots Alliance
$49.18 /

+1.36 (+2.84%)

TXN Texas Instruments
$171.48 /

-1.43 (-0.83%)

TTOO T2 Biosystems
$2.81 /

+0.715 (+34.13%)

TRMK Trustmark
$30.19 /

-0.47 (-1.53%)

SBUX Starbucks
$104.69 /

+1.34 (+1.30%)

PSNL Personalis
$42.48 /

-4.49 (-9.56%)

PLUG Plug Power
$73.14 /

+7.38 (+11.22%)

NAVI Navient
$11.88 /

+0.57 (+5.04%)

MXIM Maxim Integrated
$93.13 /

+0.77 (+0.83%)

MSFT Microsoft
$232.59 /

+3.11 (+1.36%)

LRN Stride
$26.08 /

+0.77 (+3.04%)

FFIV F5 Networks
$208.58 /

+1.33 (+0.64%)

CTMX CytomX Therapeutics
$6.92 /

-0.19 (-2.67%)

COF Capital One
$99.96 /

-2.62 (-2.55%)

CHRW C.H. Robinson
$97.35 /

-2.04 (-2.05%)

AGYS Agilysys
$49.90 /

+1.44 (+2.97%)

TRMK Trustmark
$30.19 /

-0.47 (-1.53%)

07/30/20 Raymond James
Trustmark upgraded to Market Perform at Raymond James after Q2 results
07/30/20 Raymond James
Trustmark upgraded to Market Perform from Underperform at Raymond James
04/01/20 Keefe Bruyette
Trustmark upgraded to Market Perform from Underperform at Keefe Bruyette
03/06/20 Truist
SunTrust cuts price targets on Banks amid lower interest rate environment
COF Capital One
$99.96 /

-2.62 (-2.55%)

01/19/21 JPMorgan
Capital One price target raised to $135 from $89 at JPMorgan
01/19/21 Oppenheimer
Capital One price target raised to $130 from $105 at Oppenheimer
01/06/21 Deutsche Bank
Capital One upgraded to Buy with 23% upside potential at Deutsche Bank
01/05/21 Deutsche Bank
Capital One upgraded to Buy from Hold at Deutsche Bank
MSFT Microsoft
$232.59 /

+3.11 (+1.36%)

01/25/21 Morgan Stanley
Morgan Stanley says market closer to recognizing Alphabet sum-of-the-parts value
01/25/21 DA Davidson
Box downgraded to Neutral from Buy at DA Davidson
01/22/21 RBC Capital
Varonis price target raised to $200 from $165 at RBC Capital
01/21/21 Goldman Sachs
Microsoft initiated with a Buy at Goldman Sachs
CHRW C.H. Robinson
$97.35 /

-2.04 (-2.05%)

11/30/20 Deutsche Bank
C.H. Robinson price target raised to $93 from $90 at Deutsche Bank
11/20/20 Wolfe Research
C.H. Robinson upgraded to Peer Perform from Underperform at Wolfe Research
11/09/20 Citi
C.H. Robinson upgraded to Buy from Neutral at Citi
10/29/20
Fly Intel: Top five analyst downgrades
WBA Walgreens Boots Alliance
$49.18 /

+1.36 (+2.84%)

01/15/21 Baird
Walgreens Boots Alliance price target raised to $64 from $55 at Baird
01/11/21
Fly Intel: Top five analyst upgrades
01/11/21 Baird
Baird upgrades Walgreens Boots Alliance following Q1 results
01/11/21 Guggenheim
Walgreens Boots Alliance upgraded to Buy from Neutral at Guggenheim
CTMX CytomX Therapeutics
$6.92 /

-0.19 (-2.67%)

09/22/20 Guggenheim
Guggenheim taking more conservative view, downgrades CytomX to Neutral
09/22/20 Guggenheim
CytomX Therapeutics downgraded to Neutral from Buy at Guggenheim
09/15/20 Citi
CytomX Therapeutics price target lowered to $8.50 from $11 at Citi
06/01/20 Jefferies
Jefferies 'underwhelmed' by CytomX presentations at ASCO, downgrades to Hold
LRN Stride
$26.08 /

+0.77 (+3.04%)

10/28/20 BMO Capital
K12 price target lowered to $43 from $60 at BMO Capital
09/11/20 William Blair
K12 selloff on Miami-Dade contract loss overblown, says William Blair
09/10/20 BMO Capital
K12 stock overreacting after Miami-Dade cuts ties, says BMO Capital
09/04/20 Sidoti
K12 upgraded to Buy from Neutral at Sidoti
FFIV F5 Networks
$208.58 /

+1.33 (+0.64%)

01/25/21 Cowen
F5 Networks price target raised to $255 from $223 at Cowen
01/14/21 Barclays
F5 Networks price target raised to $235 from $212 at Barclays
01/08/21 Cowen
F5 Networks price target raised to $233 from $199 at Cowen
01/08/21 Needham
F5 Networks price target raised to $235 from $210 at Needham
HOPE Hope Bancorp
$12.13 /

-0.16 (-1.30%)

MXIM Maxim Integrated
$93.13 /

+0.77 (+0.83%)

01/26/21 Barclays
Maxim Integrated price target raised to $95 from $74 at Barclays
01/25/21 Deutsche Bank
Maxim Integrated price target raised to $101 from $95 at Deutsche Bank
12/17/20 Deutsche Bank
Maxim Integrated price target raised to $95 from $90 at Deutsche Bank
11/25/20 Truist
Analog Devices price target raised to $164 from $136 at Truist
AGYS Agilysys
$49.90 /

+1.44 (+2.97%)

01/21/21 Maxim
Agilysys assumed with a Buy at Maxim
11/18/20 National Securities
Agilysys downgraded to Neutral from Buy at National Securities
11/18/20 Northland
Agilysys price target raised to $45 from $33 at Northland
10/28/20 Craig-Hallum
Agilysys price target raised to $32 from $27 at Craig-Hallum
TXN Texas Instruments
$171.48 /

-1.43 (-0.83%)

01/26/21 Barclays
Texas Instruments price target raised to $155 from $140 at Barclays
01/21/21 Oppenheimer
Texas Instruments price target raised to $185 from $180 at Oppenheimer
01/21/21 Oppenheimer
Texas Instruments price target raised to $185 from $180 at Oppenheimer
12/17/20 Deutsche Bank
Texas Instruments price target raised to $150 from $145 at Deutsche Bank
SBUX Starbucks
$104.69 /

+1.34 (+1.30%)

01/21/21 MKM Partners
Starbucks' Q1 may show slowdown in U.S. comp trends, says MKM Partners
01/19/21 Goldman Sachs
Starbucks initiated with a Buy at Goldman Sachs
01/14/21 Cleveland Research
Cleveland Research lowers Starbucks Q1 Americas comps forecast
12/16/20 Stephens
Starbucks pointed to softer U.S., stronger China than expected, says Stephens
NAVI Navient
$11.88 /

+0.57 (+5.04%)

01/19/21 JPMorgan
Navient downgraded to Neutral with $12.50 target at JPMorgan
01/19/21 JPMorgan
Navient downgraded to Neutral from Overweight at JPMorgan
10/22/20
Fly Intel: Top five analyst upgrades
10/22/20 Wedbush
Navient upgraded to Outperform at Wedbush
TTOO T2 Biosystems
$2.81 /

+0.715 (+34.13%)

11/05/20 Alliance Global Partners
T2 Biosystems price target raised to $2.60 from $1.65 at Alliance Global
10/07/20 BTIG
T2 Biosystems initiated with a Buy at BTIG
09/30/20 JonesTrading
JonesTrading reiterates $3.50 target on T2 Biosystems after BARDA contract
08/28/20 Canaccord
Hospital service channel shares weakness a buying opportunity, says Canaccord
PLUG Plug Power
$73.14 /

+7.38 (+11.22%)

01/14/21 JPMorgan
Plug Power initiated with a Neutral at JPMorgan
01/13/21 B. Riley Securities
Plug Power price target raised to $79 from $52 at B. Riley Securities
01/13/21 Craig-Hallum
Plug Power price target raised to $79 from $60 at Craig-Hallum
01/13/21 H.C. Wainwright
Plug Power price target raised to $85 from $60 at H.C. Wainwright
PSNL Personalis
$42.48 /

-4.49 (-9.56%)

01/04/21 BofA
Personalis downgraded to Neutral on valuation at BofA
01/04/21 BofA
Personalis downgraded to Neutral from Buy at BofA
12/17/20 BTIG
BTIG positive on select healthcare diagnostic/tools names as '2021 Top Picks'
12/16/20 Citi
Personalis price target raised to $45 from $35 at Citi
WBA Walgreens Boots Alliance
$49.18 /

+1.36 (+2.84%)

TXN Texas Instruments
$171.48 /

-1.43 (-0.83%)

TTOO T2 Biosystems
$2.81 /

+0.715 (+34.13%)

TRMK Trustmark
$30.19 /

-0.47 (-1.53%)

SBUX Starbucks
$104.69 /

+1.34 (+1.30%)

PSNL Personalis
$42.48 /

-4.49 (-9.56%)

PLUG Plug Power
$73.14 /

+7.38 (+11.22%)

NAVI Navient
$11.88 /

+0.57 (+5.04%)

MXIM Maxim Integrated
$93.13 /

+0.77 (+0.83%)

MSFT Microsoft
$232.59 /

+3.11 (+1.36%)

LRN Stride
$26.08 /

+0.77 (+3.04%)

HOPE Hope Bancorp
$12.13 /

-0.16 (-1.30%)

FFIV F5 Networks
$208.58 /

+1.33 (+0.64%)

CTMX CytomX Therapeutics
$6.92 /

-0.19 (-2.67%)

COF Capital One
$99.96 /

-2.62 (-2.55%)

CHRW C.H. Robinson
$97.35 /

-2.04 (-2.05%)

AGYS Agilysys
$49.90 /

+1.44 (+2.97%)

  • 27
    Jan
  • 27
    Jan
  • 21
    Jan
  • 17
    Nov
  • 12
    Aug
  • 12
    Aug
WBA Walgreens Boots Alliance
$49.18 /

+1.36 (+2.84%)

TXN Texas Instruments
$171.48 /

-1.43 (-0.83%)

SBUX Starbucks
$104.69 /

+1.34 (+1.30%)

PLUG Plug Power
$73.14 /

+7.38 (+11.22%)

MSFT Microsoft
$232.59 /

+3.11 (+1.36%)

LRN Stride
$26.08 /

+0.77 (+3.04%)

FFIV F5 Networks
$208.58 /

+1.33 (+0.64%)

COF Capital One
$99.96 /

-2.62 (-2.55%)

WBA Walgreens Boots Alliance
$49.18 /

+1.36 (+2.84%)

TXN Texas Instruments
$171.48 /

-1.43 (-0.83%)

TTOO T2 Biosystems
$2.81 /

+0.715 (+34.13%)

SBUX Starbucks
$104.69 /

+1.34 (+1.30%)

PSNL Personalis
$42.48 /

-4.49 (-9.56%)

PLUG Plug Power
$73.14 /

+7.38 (+11.22%)

NAVI Navient
$11.88 /

+0.57 (+5.04%)

MSFT Microsoft
$232.59 /

+3.11 (+1.36%)

LRN Stride
$26.08 /

+0.77 (+3.04%)

FFIV F5 Networks
$208.58 /

+1.33 (+0.64%)

CTMX CytomX Therapeutics
$6.92 /

-0.19 (-2.67%)

COF Capital One
$99.96 /

-2.62 (-2.55%)

CHRW C.H. Robinson
$97.35 /

-2.04 (-2.05%)

WBA Walgreens Boots Alliance
$49.18 /

+1.36 (+2.84%)

TXN Texas Instruments
$171.48 /

-1.43 (-0.83%)

TTOO T2 Biosystems
$2.81 /

+0.715 (+34.13%)

SBUX Starbucks
$104.69 /

+1.34 (+1.30%)

PLUG Plug Power
$73.14 /

+7.38 (+11.22%)

MSFT Microsoft
$232.59 /

+3.11 (+1.36%)

LRN Stride
$26.08 /

+0.77 (+3.04%)

FFIV F5 Networks
$208.58 /

+1.33 (+0.64%)

COF Capital One
$99.96 /

-2.62 (-2.55%)

CHRW C.H. Robinson
$97.35 /

-2.04 (-2.05%)

Periodicals
YouTube blocks Giuliani from partner program for 30 days, Bloomberg says » 18:30
01/26/21
01/26
18:30
01/26/21
18:30
GOOG

Alphabet

$1,917.51 /

+17.44 (+0.92%)

, GOOGL

Alphabet Class A

$1,908.17 /

+13.58 (+0.72%)

Alphabet's YouTube…

Alphabet's YouTube has blocked Rudy Giuliani from its partner program for at least 30 days after the former New York City mayor and Donald Trump attorney shared misinformation about the 2020 presidential election, Bloomberg's Nico Grant reports. The move indicates that Giuliani can't make money from advertising on his videos, Grant says, noting that the limitation has been in effect since last week. The former NYC mayor was also temporarily suspended from uploading videos to the service for one week, a restriction that has since expired, the author notes. Reference Link

ShowHide Related Items >><<
GOOG Alphabet
$1,917.51 /

+17.44 (+0.92%)

GOOG Alphabet
$1,917.51 /

+17.44 (+0.92%)

01/25/21 Morgan Stanley
Morgan Stanley says market closer to recognizing Alphabet sum-of-the-parts value
01/25/21 Canaccord
Alphabet price target raised to $2250 from $2050 at Canaccord
01/25/21 Mizuho
Alphabet price target raised to $2,100 from $1,810 at Mizuho
01/21/21
Fly Intel: Top five analyst initiations
GOOGL Alphabet Class A
$1,908.17 /

+13.58 (+0.72%)

01/20/21 Piper Sandler
Alphabet assumed with an Overweight at Piper Sandler
GOOGL Alphabet Class A
$1,908.17 /

+13.58 (+0.72%)

GOOG Alphabet
$1,917.51 /

+17.44 (+0.92%)

GOOG Alphabet
$1,917.51 /

+17.44 (+0.92%)

GOOG Alphabet
$1,917.51 /

+17.44 (+0.92%)

GOOGL Alphabet Class A
$1,908.17 /

+13.58 (+0.72%)

GOOG Alphabet
$1,917.51 /

+17.44 (+0.92%)

Hot Stocks
Microsoft CEO says Office 365 to see increased usage depth » 18:23
01/26/21
01/26
18:23
01/26/21
18:23
MSFT

Microsoft

$232.59 /

+3.11 (+1.36%)

Says there will be more…

Says there will be more flexibility for workers in terms of time and location - unlikely to see return to January 2020. Says the key is maintain flexibility. Comments taken from Q2 earnings conference call.

ShowHide Related Items >><<
MSFT Microsoft
$232.59 /

+3.11 (+1.36%)

MSFT Microsoft
$232.59 /

+3.11 (+1.36%)

01/25/21 Morgan Stanley
Morgan Stanley says market closer to recognizing Alphabet sum-of-the-parts value
01/25/21 DA Davidson
Box downgraded to Neutral from Buy at DA Davidson
01/22/21 RBC Capital
Varonis price target raised to $200 from $165 at RBC Capital
01/21/21 Goldman Sachs
Microsoft initiated with a Buy at Goldman Sachs
MSFT Microsoft
$232.59 /

+3.11 (+1.36%)

MSFT Microsoft
$232.59 /

+3.11 (+1.36%)

MSFT Microsoft
$232.59 /

+3.11 (+1.36%)

MSFT Microsoft
$232.59 /

+3.11 (+1.36%)

Periodicals
Goldman CEO's 2020 pay cut by 36% for 1MDB scandal, WSJ reports » 18:22
01/26/21
01/26
18:22
01/26/21
18:22
GS

Goldman Sachs

$281.79 /

-1.25 (-0.44%)

Goldman Sachs CEO David…

Goldman Sachs CEO David Solomon's 2020 compensation was cut by 36%, going from $27.5M in 2019 to $17.5M in 2020, as punishment for the lender's admission last year that it violated U.S. laws in its dealings with an investment fund at the hart of a global corruption ring, the Wall Street Journal's Peter Rudegeair reports. In October, the bank agreed to pay nearly $3B to government officials in four countries to end a probe into work it did for 1MDB, a Malaysian fund that prosecutors had claimed was used to pay bribes to politicians in Malaysia and the Middle East, the author notes. Reference Link

ShowHide Related Items >><<
GS Goldman Sachs
$281.79 /

-1.25 (-0.44%)

GS Goldman Sachs
$281.79 /

-1.25 (-0.44%)

01/22/21 Citi
Goldman Sachs price target raised to $370 from $357 at Citi
01/20/21 Credit Suisse
Goldman Sachs price target raised to $345 from $325 at Credit Suisse
01/20/21 Evercore ISI
Goldman Sachs price target raised to $325 from $288 at Evercore ISI
01/20/21 DA Davidson
Goldman Sachs price target raised to $321 from $279 at DA Davidson
GS Goldman Sachs
$281.79 /

-1.25 (-0.44%)

GS Goldman Sachs
$281.79 /

-1.25 (-0.44%)

GS Goldman Sachs
$281.79 /

-1.25 (-0.44%)

GS Goldman Sachs
$281.79 /

-1.25 (-0.44%)

Periodicals
Walgreens Boots Alliance set to name Starbucks COO Roz Brewer as CEO, WSJ says » 18:21
01/26/21
01/26
18:21
01/26/21
18:21
WBA

Walgreens Boots Alliance

$49.18 /

+1.36 (+2.84%)

, SBUX

Starbucks

$104.69 /

+1.34 (+1.30%)

, WMT

Walmart

$147.56 /

+1.32 (+0.90%)

Walgreens Boots Alliance…

Walgreens Boots Alliance (WBA) is poised to name Starbucks (SBUX) COO Roz Brewer as its next CEO, The Wall Street Journal's Dana Mattioli and Cara Lombardo report, citing people familiar with the matter. The move would set her up to be the only Black female leading a Fortune 500 company, the report noted. Brewer will replace CEO Stefano Pessina, who said in July that he would step down as CEO once Walgreens found a new leader. Pessina, one of Walgreens' biggest individual investors, said he was planning to stay on the company's board and serve as executive chairman. Prior to joining Starbucks, Brewer was CEO of Walmart's (WMT) Sams Club division. Reference Link

ShowHide Related Items >><<
WMT Walmart
$147.56 /

+1.32 (+0.90%)

WBA Walgreens Boots Alliance
$49.18 /

+1.36 (+2.84%)

SBUX Starbucks
$104.69 /

+1.34 (+1.30%)

WBA Walgreens Boots Alliance
$49.18 /

+1.36 (+2.84%)

01/15/21 Baird
Walgreens Boots Alliance price target raised to $64 from $55 at Baird
01/11/21
Fly Intel: Top five analyst upgrades
01/11/21 Baird
Baird upgrades Walgreens Boots Alliance following Q1 results
01/11/21 Guggenheim
Walgreens Boots Alliance upgraded to Buy from Neutral at Guggenheim
SBUX Starbucks
$104.69 /

+1.34 (+1.30%)

01/21/21 MKM Partners
Starbucks' Q1 may show slowdown in U.S. comp trends, says MKM Partners
01/19/21 Goldman Sachs
Starbucks initiated with a Buy at Goldman Sachs
01/14/21 Cleveland Research
Cleveland Research lowers Starbucks Q1 Americas comps forecast
12/16/20 Stephens
Starbucks pointed to softer U.S., stronger China than expected, says Stephens
WMT Walmart
$147.56 /

+1.32 (+0.90%)

01/25/21
Fly Intel: Top five analyst downgrades
01/25/21 R5 Capital
R5 Capital downgrades 'operationally challenged' Walmart to Sell
01/25/21 R5 Capital
Walmart downgraded to Sell from Hold at R5 Capital
01/22/21 Jefferies
Walmart has upside potential to $200 per share, says Jefferies
WMT Walmart
$147.56 /

+1.32 (+0.90%)

WBA Walgreens Boots Alliance
$49.18 /

+1.36 (+2.84%)

SBUX Starbucks
$104.69 /

+1.34 (+1.30%)

WMT Walmart
$147.56 /

+1.32 (+0.90%)

WBA Walgreens Boots Alliance
$49.18 /

+1.36 (+2.84%)

SBUX Starbucks
$104.69 /

+1.34 (+1.30%)

WMT Walmart
$147.56 /

+1.32 (+0.90%)

WBA Walgreens Boots Alliance
$49.18 /

+1.36 (+2.84%)

SBUX Starbucks
$104.69 /

+1.34 (+1.30%)

WMT Walmart
$147.56 /

+1.32 (+0.90%)

WBA Walgreens Boots Alliance
$49.18 /

+1.36 (+2.84%)

SBUX Starbucks
$104.69 /

+1.34 (+1.30%)

Hot Stocks
Allstate to sell Allstate Life Insurance Co. to Blackstone entities for $2.8B » 18:11
01/26/21
01/26
18:11
01/26/21
18:11
ALL

Allstate

$109.54 /

-1.4 (-1.26%)

, BX

Blackstone

$65.07 /

+0.035 (+0.05%)

The Allstate Corporation…

The Allstate Corporation (ALL) has agreed to sell Allstate Life Insurance Company to entities managed by Blackstone (BX) for $2.8B. ALIC holds approximately 80%, or $23B, of Allstate's life and annuity reserves and generated net income of $467M in 2019 and a net loss of $23M in the first nine months of 2020. The transaction is subject to regulatory approval with an expected closing in the second half of 2021. Allstate will sell ALIC and certain subsidiaries, excluding Allstate Life Insurance Company of New York, to entities managed by Blackstone for $2.8B, including a pre-closing dividend from ALIC of up to $400M. All statutory earnings from March 31, 2020, to closing, will be retained by Allstate. The transaction will reduce Allstate's GAAP reserves by $23B. Blackstone will enter into an asset management agreement for ALIC's $28B of investments. Allstate will retain ownership of ALNY, which has $5B of GAAP reserves and is pursuing alternatives to sell or otherwise transfer risk to a third party. "Allstate has been surgically deploying capital out of spread-based products with life and annuity liabilities declining to $5 billion after the closing of this transaction," said Mario Rizzo, Allstate CFO. "The investment portfolio will decline by approximately $28 billion to $63 billion. A financial book loss of approximately $3.1 billion will be recorded in the first quarter of 2021 given the lower returns on equity for the annuity businesses. Adjusted Net Income Return on Equity will increase by approximately 1 percentage point," concluded Rizzo.

ShowHide Related Items >><<
BX Blackstone
$65.07 /

+0.035 (+0.05%)

ALL Allstate
$109.54 /

-1.4 (-1.26%)

ALL Allstate
$109.54 /

-1.4 (-1.26%)

01/13/21 Gordon Haskett
Allstate lowering auto rates by 5% in several states, says Gordon Haskett
11/17/20 Barclays
Allstate initiated with an Overweight at Barclays
09/22/20 Keefe Bruyette
Allstate upgraded to Outperform from Market Perform at Keefe Bruyette
07/22/20 Citi
Citi opens 'Positive Catalyst Watch' on Allstate shares
BX Blackstone
$65.07 /

+0.035 (+0.05%)

01/14/21
Fly Intel: Top five analyst initiations
01/14/21 Piper Sandler
Blackstone initiated with an Overweight at Piper Sandler
10/29/20 Oppenheimer
Blackstone upgraded to Outperform at Oppenheimer
10/29/20 Oppenheimer
Blackstone upgraded to Outperform from Perform at Oppenheimer
BX Blackstone
$65.07 /

+0.035 (+0.05%)

ALL Allstate
$109.54 /

-1.4 (-1.26%)

BX Blackstone
$65.07 /

+0.035 (+0.05%)

BX Blackstone
$65.07 /

+0.035 (+0.05%)

ALL Allstate
$109.54 /

-1.4 (-1.26%)

BX Blackstone
$65.07 /

+0.035 (+0.05%)

Hot Stocks
Microsoft CEO says will see structurally changed tech environment post-Covid » 18:11
01/26/21
01/26
18:11
01/26/21
18:11
MSFT

Microsoft

$232.59 /

+3.11 (+1.36%)

Says company is…

Says company is benefiting from digital technology growth. Comments taken from Q2 earnings conference call.

ShowHide Related Items >><<
MSFT Microsoft
$232.59 /

+3.11 (+1.36%)

MSFT Microsoft
$232.59 /

+3.11 (+1.36%)

01/25/21 Morgan Stanley
Morgan Stanley says market closer to recognizing Alphabet sum-of-the-parts value
01/25/21 DA Davidson
Box downgraded to Neutral from Buy at DA Davidson
01/22/21 RBC Capital
Varonis price target raised to $200 from $165 at RBC Capital
01/21/21 Goldman Sachs
Microsoft initiated with a Buy at Goldman Sachs
MSFT Microsoft
$232.59 /

+3.11 (+1.36%)

MSFT Microsoft
$232.59 /

+3.11 (+1.36%)

MSFT Microsoft
$232.59 /

+3.11 (+1.36%)

MSFT Microsoft
$232.59 /

+3.11 (+1.36%)

Hot Stocks
Allstate to sell Allstate Life Insurance Co. to Blackstone entities for $2.8B  18:08
01/26/21
01/26
18:08
01/26/21
18:08
ALL

Allstate

$109.54 /

-1.4 (-1.26%)

, BX

Blackstone

$65.07 /

+0.035 (+0.05%)

 
ShowHide Related Items >><<
BX Blackstone
$65.07 /

+0.035 (+0.05%)

ALL Allstate
$109.54 /

-1.4 (-1.26%)

ALL Allstate
$109.54 /

-1.4 (-1.26%)

01/13/21 Gordon Haskett
Allstate lowering auto rates by 5% in several states, says Gordon Haskett
11/17/20 Barclays
Allstate initiated with an Overweight at Barclays
09/22/20 Keefe Bruyette
Allstate upgraded to Outperform from Market Perform at Keefe Bruyette
07/22/20 Citi
Citi opens 'Positive Catalyst Watch' on Allstate shares
BX Blackstone
$65.07 /

+0.035 (+0.05%)

01/14/21
Fly Intel: Top five analyst initiations
01/14/21 Piper Sandler
Blackstone initiated with an Overweight at Piper Sandler
10/29/20 Oppenheimer
Blackstone upgraded to Outperform at Oppenheimer
10/29/20 Oppenheimer
Blackstone upgraded to Outperform from Perform at Oppenheimer
BX Blackstone
$65.07 /

+0.035 (+0.05%)

ALL Allstate
$109.54 /

-1.4 (-1.26%)

BX Blackstone
$65.07 /

+0.035 (+0.05%)

BX Blackstone
$65.07 /

+0.035 (+0.05%)

ALL Allstate
$109.54 /

-1.4 (-1.26%)

BX Blackstone
$65.07 /

+0.035 (+0.05%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.